Table 3.

Response

	Overall, N	RERs, n (%)	CR after chemotherapy, n (%)	CR after radiation, n (%)
All patients	216	132 (63)	134 (64)	180 (90)
Evaluable		209	209	200
Intermediate risk	53	35 (67)	33 (66)	44 (96)
Stage IB	1	1	1	1
Stage IIA LMA	34	22	19	28
Stage IIIA	18	12	13	15
High risk	163	97 (61)	101 (64)	136 (88)
Stage IIB	49	34	33	43
Stage IIIB	37	27	24	32
Stage IVA	26	13	16	21
Stage IVB	51	23	28	40
“B” symptoms
No	78	46 (62)	47 (65)	62 (91)
Yes	138	86 (63)	87 (64)	118 (89)
LMA
Yes	125	79 (64)	75 (63)	103 (90)
No	79	47 (61)	53 (70)	67 (89)
Dexrazoxane
Yes	107	57 (56)*	60 (60)	87 (86)
No	109	75 (69)	74 (70)	93 (94)

Percentages were calculated excluding patients whose data were unknown. RER is defined by gallium negativity and 50% reduction in 2-dimensional tumor size after 3 cycles of chemotherapy. CR is defined by CT-based response of 70% or more at the end of chemotherapy and after radiation; those not achieving this anatomic response often had residual fibrosis rather than active disease.

^*P = .07 for difference in RERs in dexrazoxane vs no dexrazoxane.